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ABSTRACT  1 
Exhaustive single-leg exercise has been suggested to reduce time to task failure (Tlim) during 2 
subsequent exercise in the contralateral leg by exacerbating central fatigue development. We 3 
investigated the influence of acetaminophen (ACT), an analgesic which may blunt central 4 
fatigue development, on Tlim during single-leg exercise completed both with, and without, prior 5 
fatiguing exercise of the contralateral leg. Fourteen recreationally-active men performed 6 
single-leg, severe-intensity knee extensor exercise to Tlim on the left (Leg1) and right (Leg2) 7 
legs without prior contralateral fatigue, and on Leg2 immediately following Leg1 (Leg2-CONTRA). 8 
The tests were completed following ingestion of 1 g ACT or maltodextrin (placebo) capsules. 9 
Intramuscular phosphorous-containing metabolites and substrates, and muscle activation, were 10 
assessed using 31P-MRS and electromyography, respectively. Tlim was not different between 11 
the Leg1ACT and Leg1PL conditions (402 ± 101 vs. 390 ± 106 s; P>0.05). There was also no 12 
difference in Tlim between Leg2ACT-CONTRA and Leg2PL-CONTRA (324 ± 85 vs. 311 ± 92 s; P>0.05), 13 
but Tlim was shorter in these tests compared to Leg2CON (385 ± 104 s; P<0.05). There were no 14 
differences in intramuscular phosphorous-containing metabolites and substrates, or muscle 15 
activation, between the Leg1ACT and Leg1PL or the Leg2ACT-CONTRA and Leg2PL-CONTRA 16 
conditions (P>0.05). These findings suggest that task failure during single-leg severe-intensity 17 
knee extensor exercise is associated with the attainment of a similar level of metabolic 18 
perturbation and muscle activation, both with and without prior fatiguing exercise of the 19 
contralateral leg. Despite the existence of contralateral fatigue, ACT ingestion did not alter 20 
neuromuscular responses or exercise performance.  21 
 22 
Key words: 31P-magnetic resonance spectroscopy; intramuscular metabolites; intramuscular 23 
substrates; non-local muscle fatigue, paracetamol   24 
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INTRODUCTION 25 
The mechanisms of exercise-induced fatigue can be attributed to processes within the central 26 
nervous system, termed central fatigue, and within the contractile elements of the working 27 
muscle, termed peripheral fatigue. It is now recognised that peripheral and central fatigue 28 
development are interlinked, in part, via group III/IV muscle afferent feedback (25). Empirical 29 
support for a role of group III/IV muscle afferent feedback in modulating the mechanisms of 30 
neuromuscular fatigue is provided by reports that inhibiting group III/IV muscle afferent 31 
feedback, via lumbar intrathecal administration of fentanyl, lowers central fatigue development 32 
and results in increased skeletal muscle metabolic perturbation [greater and/or more rapid 33 
increases in adenosine diphosphate (ADP) and inorganic phosphate (Pi) accumulation and 34 
declines in phosphocreatine (PCr) and pH] and thus peripheral fatigue development (i.e., 1, 2, 35 
8, 10, 11, 12, 38, 39, 40). Conversely, prior fatiguing single-limb exercise has been reported to 36 
accentuate central fatigue development and lead to lower peripheral fatigue development 37 
during subsequent fatiguing exercise in a contralateral or non-local (previously rested) muscle 38 
group, when group III/IV muscle afferent feedback would be expected to be elevated (3, 22, 39 
23, 26, 33, 40). However, the underlying mechanisms of non-local muscle fatigue, including 40 
the effect of prior fatiguing single-limb exercise on skeletal muscle metabolic perturbation 41 
during subsequent fatiguing exercise in a contralateral or non-local muscle group, have yet to 42 
be resolved (ref. 23 for review). Moreover, while lumbar intrathecal administration of fentanyl 43 
and prior fatigue of a contralateral or non-local muscle group can alter group III/IV muscle 44 
afferent feedback and the physiological bases of exercise-induced neuromuscular fatigue, the 45 
effect of such interventions on exercise performance is equivocal (i.e., 1, 2, 3, 8, 10, 11, 12, 22, 46 
23, 26, 28, 33).   47 
 48 
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There is an emerging body of evidence to suggest that oral ingestion of acetaminophen (ACT) 49 
can blunt the development of exercise-induced neuromuscular fatigue and improve exercise 50 
capacity and/or performance (19, 30, 31, 32). It is generally accepted that the principal 51 
mechanism of action of ACT is the inhibition of cyclooxygenase, the enzyme that catalyses the 52 
synthesis of prostaglandins from arachidonic acid (4). Since prostaglandins sensitize 53 
nociceptors (36, 37), and since blocking cyclooxygenase attenuates group III/IV muscle 54 
afferent discharge during dynamic exercise (24), this might account for reports of increased 55 
work output for the same level of perceived pain and exertion (19, 30), and elevated muscle 56 
activation (31, 32), during exercise after ACT ingestion. Therefore, ACT administration might 57 
be ergogenic by reducing, but not abolishing, the net magnitude of group III/IV muscle afferent 58 
feedback, leading to a blunting of exercise-induced central fatigue. Since ACT appears to 59 
attenuate exercise-induced neuromuscular fatigue by abating aspects of central fatigue 60 
development (19, 30, 31, 32), ACT might be more effective at lowering exercise-induced 61 
neuromuscular fatigue following prior exhaustive exercise in a contralateral limb. However, 62 
the effects of ACT ingestion on exercise-induced fatigue development and its underlying 63 
mechanisms following prior exercise in a contralateral limb have yet to be investigated.  64 
 65 
The purpose of this study was to investigate the effects of ACT ingestion on exercise-induced 66 
neuromuscular fatigue and some of its underlying mechanisms during single-leg severe-67 
intensity knee extensor exercise completed with and without prior exhaustive severe-intensity 68 
knee extensor exercise in the contralateral leg. It was hypothesised that: 1) prior exhaustive 69 
exercise would impair subsequent exercise tolerance in the contralateral leg by lowering 70 
muscle activation and the degree of muscle metabolic perturbation [changes in muscle pH and 71 
PCr ([PCr]), ADP ([ADP]) and Pi ([Pi]) concentrations] that could be attained; 2) ACT 72 
ingestion would enhance single-leg knee extensor exercise tolerance by increasing muscle 73 
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activation (higher surface EMG) and permitting the attainment of a greater degree of muscle 74 
metabolic perturbation; and 3) ACT ingestion would improve exercise tolerance to a greater 75 
extent with, compared to without, the completion of prior exercise by the contralateral leg. 76 
 77 
MATERIALS AND METHODS 78 
Subjects 79 
Fourteen active males volunteered to participate in this study (mean ± SD: age 23.8 ± 4.7 y, 80 
height 1.80 ± 0.10 m, body mass 81.6 ± 14.9 kg). All procedures were approved by the Ethics 81 
Committee of the Department of Sport and Health Sciences, University of Exeter. This study 82 
conformed to the principles of the World Medical Association Declaration of Helsinki. 83 
Subjects completed a health questionnaire, which was checked by a medical doctor, to ensure 84 
it was safe to consume ACT prior to performing exhaustive exercise. The questionnaire 85 
incorporated questions pertaining to: known allergies to medications, current intake of 86 
medication and prior use of ACT as well as any history of illnesses, cigarette and illegal drug 87 
use, alcohol consumption, and chronic illnesses (personal and family history). Prior to each 88 
visit, subjects were required to refrain from caffeine (for at least 12 h), strenuous exercise and 89 
alcohol (for at least 24 h), analgesics and any form of anti-inflammatory drug (for the duration 90 
of the experiment) and to arrive in a fully rested, hydrated state. With the exception of these 91 
restrictions, subjects were instructed to maintain their usual diet and exercise regime during the 92 
study. All tests were performed at a similar time of day (± 2 h).  93 
 94 
Pre-experimental procedures 95 
Subjects visited the laboratory on twelve occasions over an 8-12 week period to complete the 96 
experimental testing, with a minimum of 72 h separating all tests (figure 1). The experimental 97 
testing incorporated 4 pre-experimental trials (visits 1-4) and 8 experimental trials (visits 5-98 
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12). Visits 1-4 were completed within a replica of an MRI scanner (with no magnetic field 99 
present). Initially, subjects completed a single-limb incremental test on the left leg (visit 1, 100 
Leg1) and right leg (visit 2, Leg2) to task failure to establish the limb-specific work rates that 101 
would be applied in subsequent experimental visits (as described below). Following these 102 
preliminary tests, subjects completed a familiarisation session on visits 3 and 4 which 103 
comprised a single-leg severe-intensity constant work rate (CWR) test to task failure with the 104 
left leg (Leg1), a single-leg severe-intensity CWR test to task failure with the right leg (Leg2), 105 
and a crossover test where the Leg1 protocol was repeated and immediately followed by the 106 
Leg2 protocol to assess contralateral fatigue in Leg2. In these preliminary tests, the Leg1, Leg2 107 
and Leg2 contralateral protocols were interspersed by 10 min of passive recovery.   108 
 109 
Experimental procedures 110 
During visits 5 and 6, subjects completed the Leg1 and Leg2 protocols without oral consumption 111 
of any capsules (Leg1CON and Leg2CON, respectively). On visits 7 and 8, subjects completed the 112 
crossover limb tests described above, 45 mins following the consumption of 1 g maltodextrin 113 
(placebo, PL) to determine time to task failure (Tlim) values for Leg1 (Leg1PL) and Leg2 114 
contralateral (Leg2PL-CONTRA), and 45 mins following the consumption of 1 g ACT, to determine 115 
Tlim values for Leg1 (Leg1ACT) and Leg2 contralateral (Leg2ACT-CONTRA). PL and ACT were 116 
administered in the form of 2 identically coloured pills. The placebo was made from 117 
maltodextrin powder inserted into gelatine capsules designed to have a similar appearance to 118 
ACT without inducing any analgesic or antipyretic effects. The oral consumption of PL and 119 
ACT ~45 min prior to commencing exercise was selected to broadly coincide with attainment 120 
of the peak plasma [ACT], which occurs ~60 min post ACT ingestion (4, 17), at the onset of 121 
the Leg2-CONTRA tests. The PL and ACT conditions were administered double-blind in a 122 
counterbalanced cross-over experimental design. Visits 5-8 were completed within the bore of 123 
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an MRI scanner for assessment of exercise-induced changes in intramuscular phosphorous-124 
containing substrates and metabolites. Visits 5-8 were replicated in visits 9-12 within a replica 125 
of the MRI scanner (with no magnetic field present) to assess muscle electromyography (EMG) 126 
and ratings of perceived exertion (RPE).   127 
 128 
Experimental set-up  129 
Exercise tests were performed in a prone position within the bore of a 1.5 T superconducting 130 
magnet (Gyroscan Clinical Intera, Philips, The Netherlands) using a custom-built ergometer 131 
for the assessment of intra-muscular [PCr], [Pi], [ADP] and pH (visits 5-8) or within a replica 132 
of the MRI scanner for preliminary testing (visits 1-4) and the assessment of EMG and RPE 133 
responses (visits 9-12). Subjects’ feet were fastened securely to padded foot braces using 134 
Velcro straps and connected to the ergometer load baskets via a rope and pulley system. The 135 
sprocket arrangement was such that when a bucket containing non-magnetic weights was 136 
attached, it provided a concentric-only resistive load, allowing for the performance of rhythmic 137 
knee-extension exercise. Single-leg knee-extensions over a distance of ∼0.22 m were 138 
performed continuously at a constant frequency which was set in unison with the magnetic 139 
pulse sequence (40 pulses min−1) to ensure the quadriceps muscle was in the same phase of 140 
contraction during each magnetic resonance pulse acquisition. To prevent displacement of the 141 
quadriceps relative to the magnetic resonance spectroscopy (MRS) coil, Velcro straps were 142 
also fastened over the subject's thighs, hips and lower back.  143 
 144 
Experimental protocol 145 
To determine peak work rate (WRpeak) for each leg, subjects initially completed single-leg 146 
incremental knee-extensor exercise on visits 1 and 2 until they were unable to continue the 147 
prescribed work rate, as described previously (43). The load for the initial increment was 4 kg 148 
8 
 
and this was increased by 0.5 kg·min-1 thereafter until Tlim. Tlim was recorded when subjects 149 
were unable to sustain the required contraction frequency for 3 consecutive repetitions. 150 
Following these initial tests, subjects were familiarized with the different exercise tests that 151 
comprised the experimental testing protocol. During these visits, a limb-specific, high-intensity 152 
work rate, which was expected to elicit Tlim in approximately 5–8 min, was prescribed for each 153 
subject.  154 
 155 
The experimental exercise protocol consisted of CWR, single-leg knee-extension to Tlim. 156 
Initially, subjects completed single-leg knee-extension exercise for each limb individually over 157 
two separate laboratory visits. Subsequently, to investigate the influence of ACT on 158 
contralateral leg fatigue, subjects completed single-leg knee-extension exercise until task 159 
failure with Leg1, followed consecutively (<3 s) by the identical task with the contralateral leg 160 
(i.e., Leg2). These crossover tests to assess contralateral fatigue in Leg2 were completed 60 min 161 
following the consumption of PL and ACT over two separate laboratory visits. For all trials, 162 
subjects received strong verbal encouragement to continue for as long as possible but no 163 
feedback was given on the elapsed time.   164 
 165 
MRS measurements 166 
31P-MRS data were acquired every 1.5 s with a spectral width of 1,500 Hz and 1,000 data 167 
points. Phase cycling with four phase cycles was used, leading to a spectrum being acquired 168 
every 6 s. The subsequent spectra were quantified by peak fitting, using the AMARES fitting 169 
algorithm in the jMRUI (v3) software package. Absolute values of [PCr] and [Pi] 170 
concentrations were subsequently calculated via the ratio of PCr:adenosine triphosphate (ATP) 171 
and Pi:ATP assuming an ATP concentration of 8.2 mM. Intracellular pH was calculated using 172 
the chemical shift of the Pi spectra relative to the PCr peak. The ADP concentration was 173 
9 
 
calculated as described by Kemp et al. (27). In all cases, relative amplitudes were corrected for 174 
partial saturation resulting from the short repetition time relative to T1 relaxation time, via a 175 
spectrum consisting of 24 averages that was acquired with a TR of 20 s prior to the 176 
comencement of exercise testing. 177 
 178 
Electromyography 179 
Throughout visits 9-12, muscle activity of the right and left m.vastus lateralis was recorded 180 
using active bipolar bar electrodes with a single differential configuration (DE2.1, DelSys Inc, 181 
Boston, MA, USA). Initially, the leg was shaved and cleaned with alcohol to minimize skin 182 
impedance. The electrodes were placed over the respective muscle bellies parallel to the 183 
longitudinal axis of each muscle (SENIAM guidelines). Double-sided adhesive tape and a 184 
hypoallergenic medical tape were used to ensure the EMG sensor stability. The position of the 185 
EMG electrodes was measured with respect to the location of the patella and the anterior 186 
superior iliac spine and marked with indelible ink to ensure placement in the same location on 187 
subsequent visits. The ground electrode was placed over the patella of the respective leg. The 188 
EMG signals were pre-amplified (1,000x), band-pass filtered (20–450 Hz, Bagnoli-8, DelSys 189 
Inc, Boston, MA, USA), and then transferred to a computer with a sampling frequency of 2 190 
kHz. EMG data were recorded continuously and digitised synchronously with 16 bit resolution 191 
via an A/D converter (± 5 V range, CED 1401 power, Cambridge, UK) using Spike2 software 192 
(CED, Cambridge, UK). During these trials, ratings of perceived exertion (RPE) was measured 193 
at 2-min intervals from the onset of exercise using Borg’s 6-20 scale (9). 194 
 195 
Data Analysis 196 
Baseline values for [PCr], [Pi], [ADP], and pH were defined as the mean values measured over 197 
the final 60 s of rest (i.e., prior to initiation of the severe-intensity exercise bout). Baseline 198 
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values for Leg2 during the crossover protocol (for both PL and ACT) were calculated during 199 
the final 60 s of exhaustive Leg1 exercise. End-exercise values for these variables were defined 200 
as the mean values measured over the final 30 s of exercise. The changes (Δ) in [PCr], [Pi], 201 
[ADP] and pH across the protocol were then calculated as the difference between end-exercise 202 
and baseline values. [PCr], [Pi] and [ADP] were expressed as absolute concentrations and as a 203 
percentage change relative to resting baseline (i.e., 100%). The overall rate of change for [PCr], 204 
[Pi], [ADP] and pH was calculated as the difference between end-exercise and baseline values 205 
divided by Tlim. EMG was average rectified and normalised to the first 30 s of each trial 206 
(aEMG). For analysis, Tlim values obtained from visits 5-8 were used. Visits 9-12 were used to 207 
overlay EMG and RPE responses to 31P-MRS data. 208 
 209 
Statistics 210 
Differences in Tlim, baseline and end-exercise aEMG and muscle [PCr], [Pi], [ADP], and pH 211 
between control limbs (i.e., Leg1 vs. Leg2) were assessed using paired samples t-tests. A two-212 
way repeated measures ANOVA (time x condition) was employed to test for differences in the 213 
profiles of muscle [PCr], [Pi], [ADP] and pH,  aEMG (using 30 s mean values), and RPE (using 214 
120 s mean values). Where the ANOVA revealed a significant main or interaction effect, post-215 
hoc tests were completed using a Bonferroni correction. For calculation of effect size, partial 216 
eta squared (η2) was used for omnibus tests. Cohen's d was used to calculate the effect size for 217 
paired t-tests and post-hoc comparisons. Where sphericity was violated, a greenhouse-geisser 218 
correction factor was applied. For all tests, results were considered statistically significant 219 
when P<0.05. Data are presented as means ± SD unless otherwise indicated. All statistical 220 
analyses were conducted using IBM SPSS Statistics version 24. 221 
 222 
RESULTS 223 
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There was no difference in Tlim during the Leg1CON (396 ± 105 s) and Leg2CON (385 ± 104 s) 224 
protocols (P>0.05, d=0.10, figure 2). Moreover, there were no differences in [PCr], [Pi], [ADP], 225 
pH (table 1, figure 3), aEMG amplitude (table 2, figure 5) and RPE (figure 6) between Leg1CON 226 
and Leg2CON at any time (all P>0.05). Compared to Leg2CON, Tlim was reduced by 19% when 227 
Leg2 was preceded by exhaustive exercise in Leg1 following the consumption of PL (Leg2CON: 228 
385 ± 104 s vs. Leg2PL-CONTRA: 311 ± 92 s, P<0.01, d=0.76, figure 2).  229 
 230 
Effect of ACT on single-leg exercise tolerance and contralateral leg fatigue 231 
There was no difference in Tlim between the Leg1CON (396 ± 105 s), Leg1ACT (402 ± 101 s) and 232 
Leg1PL (390 ± 106 s) conditions (P>0.05, η2=0.07, figure 2). Both Leg2PL-CONTRA and Leg2ACT-233 
CONTRA Tlim were significantly lower compared to Leg2CON (P<0.05, η2=0.71, figure 2).  234 
However, there was no difference in Tlim between Leg2PL-CONTRA and Leg2ACT-CONTRA (311 ± 92 235 
s vs. 324 ± 85 s, respectively, d=0.15, P>0.05, figure 2).  236 
 237 
Muscle metabolic measurements 238 
The [PCr], [Pi], [ADP] and pH profiles are illustrated in figure 3 for Leg1PL and Leg1ACT and in 239 
figure 4 for Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA, respectively. There were no 240 
significant differences in [PCr], [Pi], [ADP] or pH measured at any time points between 241 
Leg1CON and Leg2CON (P>0.05, table 1, figure 3). Similarly, there were no differences in end-242 
exercise [PCr] (Leg2CON: 16.0 ± 3.0,  Leg2PL-CONTRA: 16.1 ± 2.4, Leg2ACT-CONTRA: 15.7 ± 2.6 243 
mM, η2=0.13), [ADP] (Leg2CON: 57.8 ± 20.7, Leg2PL-CONTRA: 56.4 ± 16.8, Leg2ACT-CONTRA: 55.3 244 
± 17.8 µM, η2=0.09) and pH (Leg2CON: 6.83 ± 0.15, Leg2PL-CONTRA: 6.83 ± 0.20, Lbeg2ACT-245 
CONTRA: 6.80 ± 0.15, η2=0.05) between the Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA 246 
conditions (P>0.05, table 1, figure 4). However, end-exercise [Pi] was significantly lower in 247 
Leg2PL-CONTRA and Leg2ACT-CONTRA compared to Leg2CON (Leg2CON: 21.8 ± 3.7, Leg2PL-CONTRA: 248 
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18.8 ± 4.1, Leg2ACT-CONTRA: 18.7 ± 3.9 mM, P=0.04, η2=0.89, table 1, figure 4). Baseline [PCr] 249 
was significantly higher (36.6 ± 2.1 vs. 33.2 ± 3.2 vs. 33.2 ± 3.1 mM, P<0.0001, η2=3.04), and 250 
[Pi] (Pi: 3.96 ± 0.7  vs. 5.2 ± 1.1 vs. 5.2 ± 1.0 mM, P<0.01, η2=2.13) and [ADP] (ADP: 5.8 ± 251 
1.2 vs. 11.4 ± 4.3 vs. 11.4 ± 4.5 µM, P<0.01, η2=2.55, table 1, figure 4) were significantly 252 
lower, in Leg2CON when compared to Leg2PL-CONTRA and Leg2ACT-CONTRA, respectively. The rates 253 
of change for [Pi] (0.05 ± 0.01 vs. 0.05 ± 0.02 vs. 0.05 ± 0.02 mM/s, P>0.05, η2=0.10), [PCr] 254 
(-0.06 ± 0.02 vs. -0.06 ± 0.04 vs. -0.06 ± 0.03 mmol/s, P>0.05, η2=0.11), [ADP] (0.15 ± 0.09 255 
vs. 0.17 ± 0.10 vs. 0.15 ± 0.09 µM/s, P>0.05, η2=0.17) and pH (P>0.05, η2=0.08) were not 256 
different between the Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA conditions, respectively.  257 
 258 
Electromyography (n=10) 259 
aEMG amplitude of m. vastus lateralis rose significantly from the first minute of exercise to 260 
end-exercise in all conditions (figure 5; P<0.01, η2=3.8). However, there were no differences 261 
in aEMG between Leg1CON, Leg1PL and Leg1ACT at Tlim (Leg1CON: 229 ± 54, Leg1PL: 224 ± 43, 262 
Leg1ACT: 238 ± 51%, P=0.69, η2=0.09, table 2, figure 5). End-exercise aEMG in Leg2CON was 263 
also similar to Leg2PL-CONTRA and Leg2ACT-CONTRA, respectively (Leg2CON: 234 ± 52, Leg2PL-264 
CONTRA: 226 ± 58, Leg2ACT-CONTRA: 242 ± 52%, P=0.69, η2=0.20, table 2, figure 5). However, 265 
absolute aEMG was elevated at the start of Leg2PL-CONTRA and Leg2ACT-CONTRA exercise when 266 
compared to Leg2CON (Leg2CON: 0.04 ± 0.02, Leg2PL-CONTRA: 0.05 ± 0.02, Leg1ACT-CONTRA: 0.05 267 
± 0.02 mV, P<0.05, η2=0.58, table 2, figure 5). 268 
 269 
Ratings of perceived exertion 270 
RPE increased in all trials following the onset of exercise (figure 6). However, there were no 271 
differences in RPE between Leg1CON, Leg1PL and Leg1ACT at any time point (P>0.05, η2=0.08, 272 
figure 6). The rate of rise and the end-exercise RPE were also similar during the Leg2CON trial 273 
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compared with the Leg2PL-CONTRA and Leg2ACT-CONTRA trials (P>0.05, η2=0.18). However, at 274 
the onset of exercise, RPE was significantly higher in Leg2PL-CONTRA and Leg2ACT-CONTRA when 275 
compared to Leg2CON (P<0.05, η2=0.55, figure 6). Specifically, during the first 2 min of 276 
exercise, there was a respective elevation in RPE of 14% and 13% in Leg2PL-CONTRA and 277 
Leg2ACT-CONTRA, compared to Leg2CON (P<0.05). There were no differences in RPE at any time 278 
points between Leg2PL-CONTRA and Leg2ACT-CONTRA (P>0.05, η2=0.21, figure 6).  279 
 280 
DISCUSSION 281 
The principal original finding of this study was that, while time to task failure was lower during 282 
severe-intensity single-leg knee extensor exercise after the completion of prior fatiguing 283 
exercise in the contralateral leg, this effect was not mitigated by acute ACT ingestion. We 284 
found no differences in the rates of change or end-exercise values for skeletal muscle activation 285 
(via EMG), metabolic perturbation (via 31P-MRS) and perception of effort (via RPE) during 286 
exercise after prior contralateral leg fatigue following ACT and PL ingestion. Moreover, there 287 
were also no differences in time to task failure (i.e., Tlim), skeletal muscle activation, metabolic 288 
perturbation and RPE during single-leg exercise without the completion of prior fatiguing 289 
exercise in the contralateral leg following ACT and PL ingestion. These findings do not support 290 
our experimental hypotheses and suggest that 1 g of acute ACT ingestion does not improve 291 
time to task failure, skeletal muscle activation, metabolic perturbation or perceived exertion 292 
during single-leg severe-intensity knee extensor exercise completed with or without prior 293 
fatiguing exercise by the contralateral leg. Collectively, these results contribute to our 294 
understanding of fatigue development during exercise, performed with or without prior 295 
contralateral leg exercise, and in the presence or absence of ACT ingestion.  296 
 297 
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In the present study, Tlim in the Leg2PL-CONTRA protocol was shorter than the Leg2CON protocol, 298 
indicative of an earlier task failure after completing exhaustive exercise in the contralateral leg 299 
compared to no prior fatiguing contralateral leg exercise. This observation is consistent with 300 
some (i.e., 3, 14, 22, 29, 33, 41), but not all (i.e., 16, 21, 34, 42, 45), previous studies reporting 301 
greater fatigue development after prior contralateral or non-local muscle fatigue. While the 302 
neuromuscular bases of contralateral fatigue development have yet to be fully resolved (23), 303 
there is evidence to suggest that greater central fatigue makes an important contribution to this 304 
phenomenon (3).  In the current study, RPE was higher at baseline and over the initial stages 305 
of the Leg2PL-CONTRA test compared to the Leg2CON test, leading to an earlier attainment of peak 306 
RPE and Tlim, consistent with previous observations (3) and the notion that afferent feedback 307 
may contribute to increased pain and effort sensation (1, 20). Amann and colleagues (3) 308 
reported a lower EMG response at task failure and reduced peripheral fatigue development 309 
after prior contralateral leg fatigue. Although the EMG amplitude was not different at task 310 
failure in the current study between the Leg2CON and Leg2PL-CONTRA tests, baseline EMG was 311 
elevated in the Leg2PL-CONTRA condition, presumably due to isometric stabilisation, leading to 312 
the earlier attainment of the same peak EMG amplitude. The greater muscle activation in the 313 
non-exercising contralateral leg during the baseline ‘resting’ period in the Leg2PL-CONTRA 314 
condition was accompanied by lower muscle [PCr], and higher muscle [Pi] and [ADP], 315 
compared to the Leg2CON condition. Since there were no differences in muscle [PCr] and [ADP] 316 
at Tlim, and since the rates of change in [PCr] and [ADP] were not different between the Leg2CON 317 
and Leg2PL-CONTRA tests, the muscle [PCr] nadir and [ADP] peak were attained earlier in the 318 
Leg2PL-CONTRA test. These observations cohere with reports that the end-exercise values of 319 
muscle [PCr], [ADP] and pH are consistent when several bouts of exhaustive exercise of 320 
differing duration are completed within the severe-intensity domain (7, 44), and when Tlim is 321 
altered via prior passive heating of the legs (6) or by hyperoxic gas inhalation (44). 322 
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Interestingly, however, and despite a higher baseline muscle [Pi] in the Leg2PL-CONTRA condition 323 
compared to the Leg2CON condition, muscle [Pi] was lower at the point of task failure in the 324 
Leg2PL-CONTRA test. These novel observations suggest that the ergolytic effect of prior 325 
contralateral fatigue may be related, at least in part, to a limitation in the attainment of peak 326 
intramuscular [Pi].   327 
 328 
It is unclear why prior contralateral leg fatigue limited the attainment of peak [Pi] in the Leg2PL-329 
CONTRA condition compared to the Leg2CON condition, whereas the peak [ADP] and the nadir in 330 
pH and [PCr] were not different between these conditions. However, our observations of a 331 
limited peak perturbation of muscle [Pi], but not pH, [PCr] and [ADP], when group III/IV 332 
muscle afferent feedback would be expected to be elevated via prior contralateral fatigue (3), 333 
are in accord with  studies from another group who observed greater peak perturbation of 334 
muscle [Pi], but not pH, [PCr] and [ADP], when group III/IV muscle afferent feedback was 335 
abolished via lumbar intrathecal administration of fentanyl (8, 11, 12). Taken together, these 336 
complementary observations suggest that intramuscular phosphorous-containing metabolites 337 
and substrates may not respond in a uniform manner to manipulations in skeletal muscle group 338 
III/IV afferent feedback and that muscle [Pi] might be a more sensitive marker of peripheral 339 
fatigue development. However, it should be acknowledged that, since inter-test variability is 340 
greater for contracting skeletal muscle [Pi] than for pH, [PCr] and [ADP] (15), further research 341 
is required to verify these observations.    342 
 343 
Although the completion of prior single-leg fatiguing exercise lowered Tlim during subsequent 344 
exercise in the contralateral leg in the current study, there were no differences between the 345 
Leg2ACT-CONTRA and Leg2PL-CONTRA conditions in Tlim, RPE, or muscle activation and 346 
phosphorous-containing metabolites and substrates. Similarly, and also in contrast to our 347 
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hypothesis, acute ACT ingestion did not alter Tlim, RPE, or muscle activation, pH, [PCr], [ADP] 348 
or [Pi], during single-leg severe-intensity knee extensor exercise completed without prior 349 
fatiguing exercise in the contralateral leg, with these responses being similar between the 350 
Leg1CON, Leg1PL and Leg1ACT conditions. These findings conflict with reports that acute ACT 351 
consumption can improve exercise performance by increasing work output for the same level 352 
of pain and effort sensation (19, 30) and by increasing muscle activation (31, 32).  353 
 354 
Experimental Considerations  355 
The lack of an ergogenic effect of ACT administration in the current study might be due to 356 
differences in the ACT administration procedure compared to previous studies reporting 357 
improved performance and delayed neuromuscular fatigue development (19, 30, 31, 32). In the 358 
present study, ACT was ingested 45 min prior to the start of the Leg1ACT test, which 359 
immediately transitioned into the Leg2ACT-CONTRA protocol that was the primary focus of the 360 
current study. Since peak plasma [ACT] is attained ~60 min post oral ACT ingestion (4, 17), 361 
we elected to administer ACT such that peak plasma [ACT] was expected to coincide with the 362 
onset of the Leg2ACT-CONTRA protocol rather than the Leg1ACT protocol. This might account for 363 
the lack of an ergogenic effect of ACT during the Leg1ACT protocol compared to other studies 364 
that administered ACT 60 min prior to the performance trial (19, 30, 31, 32). Therefore, we 365 
cannot exclude the possibility that earlier ACT ingestion (18), at the same or a greater dose 366 
(19, 30), might have resulted in improved single-leg severe-intensity exercise tolerance. 367 
However, it should also be noted that inter-study differences in participant characteristics (i.e., 368 
training status, motivation and responsiveness to analgesic medication) may have contributed 369 
to the differences in ergogenicity observed following ACT ingestion between the current study 370 
and some previous studies (19, 30, 31, 32).  371 
 372 
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In addition to differences in the ACT dosing procedure, the lack of an ergogenic effect of ACT 373 
administration in the current study might be linked to the nature of the fatiguing exercise test 374 
administered. Our subjects completed continuous single-leg severe-intensity knee extensor 375 
exercise until task failure with no pre-determined end-point (i.e., an ‘open loop’ exercise test). 376 
This differs from situations in which ACT ingestion has been reported to be ergogenic, such as 377 
completion of a fixed distance (16.1 km) time trial (30), a fixed number of maximal effort 378 
repetitions (19, 31), or a fixed duration of maximal effort (32), all of which have a 379 
predetermined end point (i.e., a ‘closed loop’ exercise task). Moreover, since exercise-induced 380 
pain sensation is positively associated with exercise intensity (5, 13), and since ACT ingestion 381 
is suggested to be ergogenic by mitigating pain sensation (19, 30), this might account for the 382 
lack of improvement in performance in the longer duration, continuous severe-intensity 383 
exercise test we employed compared to the improved exercise performance that has been 384 
reported during maximal-intensity exercise (19, 31, 32). With regard to contralateral fatigue 385 
development, we cannot exclude the possibility that ACT might have been effective at 386 
attenuating the effects of prior single-leg fatigue on Tlim during subsequent exercise if a greater 387 
degree of contralateral fatigue had been attained. For example, Tlim was lowered by 19% in 388 
Leg2PL-CONTRA compared to Leg2CON in the current study, whereas Amann et al. (3) reported a 389 
much larger (49%) reduction in Tlim following contralateral limb fatigue, which would have 390 
provided greater scope for an ergogenic effect with ACT ingestion. Moreover, since RPE is 391 
higher and Tlim is shorter at the same relative exercise intensity when a larger muscle mass is 392 
recruited (35), it is possible that ACT ingestion might have improved Tlim during exercise after 393 
prior fatigue had a larger muscle mass been recruited in either the initial or the subsequent 394 
fatiguing exercise task. Further research is required to assess the exercise settings in which 395 
ACT administration is more or less likely to be ergogenic.   396 
 397 
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In conclusion, the completion of prior single-leg fatiguing exercise compromised exercise 398 
tolerance during subsequent exercise in the contralateral leg. This ergolytic effect of prior 399 
contralateral leg fatigue was accompanied by elevated baseline RPE, muscle activation and 400 
[ADP], and lower baseline [PCr], leading to the earlier attainment of peak (RPE, muscle 401 
activation and [ADP]) or nadir (muscle [PCr]) values in these variables, and the attainment of 402 
a submaximal end-exercise [Pi]. However, acute ACT ingestion was not effective at lowering 403 
perceived exertion, increasing muscle activation or intramuscular perturbation or enhancing 404 
Tlim during single-leg severe-intensity exercise completed with or without prior fatigue in the 405 
contralateral leg. These findings do not support an ergogenic effect of analgesia, at least using 406 
the ACT administration and exercise testing procedures employed in the current study.   407 
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Tables with their headings 593 
Table1. Muscle metabolic responses in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA conditions. 
 Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-CONTRA Leg2ACT-CONTRA 
       
Muscle metabolic response       
[PCr]       
Baseline PCr (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 92 ± 5* 93 ± 4* 
PCr at 120 s (%) 70 ± 8 70 ± 8 71 ± 47 71 ± 8 62 ± 9* 63 ± 7* 
End-exercise PCr (%) 42 ± 9 41 ± 9 41 ± 8 44 ± 8 45 ± 7 44 ± 8 
Rate of change PCr (mmol/s) -0.06 ± 0.01 -0.06 ± 0.03 -0.06 ± 0.02 -0.05 ± 0.03 -0.06 ± 0.04 -0.06 ± 0.03 
       
[Pi]       
Baseline Pi (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 125 ± 24* 126 ± 23* 
Pi at 120 s (%) 310 ± 66 313 ± 71 306 ± 62 312 ± 66 316 ± 70 318 ± 64 
End-exercise Pi (%) 590 ± 149 590 ± 137 594 ± 156 588 ± 177 459 ± 110* 460 ± 109* 
Rate of change Pi (mmol/s) 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 0.05 ± 0.02 
       
[ADP]       
Baseline ADP (%) 100 ± 0 100 ± 0 100 ± 0 100 ± 0 200 ± 78* 201 ± 77* 
ADP at 120 s (%) 404 ± 161 415 ± 183 400 ± 148 412 ± 170 538 ± 176 516 ± 154* 
End-exercise ADP (%) 1028 ± 386 1036 ± 421 1046 ± 409 1024 ± 401 980 ± 316 978 ± 312 
Rate of change ADP (µmol/s) 0.15 ± 0.08 0.15 ± 0.09 0.14 ± 0.07 0.15 ± 0.09 0.17 ± 0.10 0.15 ± 0.09 
       
pH       
Baseline pH 7.04 ± 0.01 7.03 ± 0.02 7.05 ± 0.04 7.04 ± 0.03 7.04 ± 0.03 7.05 ± 0.02 
pH at 120 s 6.96 ± 0.09 6.94 ± 0.07 6.92 ± 0.08 6.95 ± 0.08 6.93 ± 0.10 6.94 ± 0.08 
End-exercise pH 6.77 ± 0.18 6.76 ± 0.15 6.76 ± 0.16 6.83 ± 0.15 6.83 ± 0.20 6.80 ± 0.15 
       
PL, placebo; ACT, acetaminophen; EMG, electromyography; PCr, Phosphocreatine; Pi, Inorganic Phosphate; ADP, Adenosine diphosphate; 
*significantly different from Leg2CON,, P<0.05 
594 
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Tables 595 
Table2. Electromyography (EMG) responses of m. vastus lateralis in Leg1CON, Leg1PL, Leg1ACT, Leg2CON, Leg2PL-CONTRA and Leg2ACT-CONTRA 
conditions.  
 Leg1CON Leg1PL Leg1ACT Leg2CON Leg2PL-
CONTRALATERAL 
Leg2ACT-
CONTRALATERAL 
       
Neuromuscular function       
Baseline EMGRMS amplitude 
(mV) 
 
0.04 ± 0.01  0.04 ± 0.02 0.04 ± 0.02 0.04 ± 0.02 0.05 ± 0.02* 0.05 ± 0.02* 
End-exercise EMGRMS 
amplitude (%) 
 
229 ± 54 224 ± 43 238 ± 51 234 ± 52 226 ± 58 242 ± 52 
EMGRMS amplitude at 120 s 
(%) 
150 ± 27  160 ± 25 166 ± 26 158 ± 29 155 ± 32 158 ± 34 
       
PL, placebo; ACT, acetaminophen; EMG, electromyography; RMS, root mean square; *significantly different from Leg2CON, P<0.05. Data are 
from 10 subjects. 
596 
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Legends to figures 597 
Figure 1 598 
Protocol schematic. Visits 1-4 were completed within a replica of the MRI scanner. Subjects 599 
completed a single-leg incremental test on the left leg (visit 1, Leg1) and right leg (visit 2, Leg2). 600 
Subjects then completed a familiarisation session on visits 3 and 4 which comprised a single-601 
leg severe-intensity constant work rate (CWR) test to task failure with Leg1, Leg2 and a 602 
crossover test where the Leg1 protocol was repeated and immediately followed by the Leg2 603 
protocol (interspersed by 10 min of passive recovery). During visits 5 and 6, subjects completed 604 
the Leg1 and Leg2 protocols, respectively, without oral consumption of any capsules. On visits 605 
7 and 8, subjects commenced the crossover test, 45 mins following the consumption of 1 g 606 
maltodextrin (PL) and 45 mins following the consumption of 1 g ACT. Visits 5-8 were 607 
completed within the bore of an MRI scanner for assessment of intramuscular phosphorous 608 
substrates and metabolites and then replicated within a replica of the MRI scanner (visits 9-12) 609 
to assess muscle electromyography (EMG) and ratings of perceived exertion (RPE). The 610 
dashed vertical lines represent the limit of tolerance (i.e., Tlim) for each trial and/or leg, 611 
respectively.  612 
 613 
Figure 2 614 
Exercise tolerance (time to task failure, s) in Leg1CON, Leg2CON, Leg1PL, Leg2PL-CONTRA, Leg1ACT 615 
and Leg2ACT-CONTRA conditions. Data are presented as mean ± SD *significantly different from 616 
Leg1CON, Leg2CON; Leg1PL and Leg1ACT (P<0.05). 617 
 618 
Figure 3 619 
Intramuscular phosphocreatine concentration ([PCr]; panel A), inorganic phosphate 620 
concentration ([Pi]; panel B), adenosine diphosphate ([ADP]; panel C) and pH (panel D) during 621 
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severe-intensity, single-leg knee-extensor exercise in the left leg following PL ingestion 622 
(Leg1PL, filled circles) and ACT (Leg1ACT, clear circles) ingestion. Data are expressed as group 623 
mean ± SE. 624 
 625 
Figure 4 626 
Intramuscular phosphocreatine concentration ([PCr]; panel A), inorganic phosphate 627 
concentration ([Pi]; panel B), adenosine diphosphate ([ADP]; panel C) and pH (panel D) during 628 
severe-intensity, single-leg knee-extensor exercise in the right control leg (Leg2CON, open 629 
triangles) and in the right leg following prior exhaustive exercise in the left leg after PL 630 
ingestion (Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) ingestion. Data 631 
are expressed as group mean ± SE. *Tlim significantly different from Leg2PL-CONTRA and 632 
Leg2ACT-CONTRA (P<0.05); 
#significantly different from Leg2PL-CONTRA and Leg2ACT-CONTRA 633 
(P<0.05). 634 
 635 
Figure 5 636 
Surface electromyography (EMG) of the m.vastus lateralis muscle during severe-intensity, 637 
single-leg knee-extensor exercise in Leg1PL (filled circles) and Leg1ACT (clear circles) (panel 638 
A), and in the right control leg (Leg2CON, open triangles), and in Leg2 following prior exhaustive 639 
exercise in Leg1 after PL (Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) 640 
ingestion (panel B). Mean values for average rectified EMG (aEMG) during each muscle 641 
contraction were calculated and averaged over each 30-s period. Data are expressed as group 642 
mean ± SE relative to the first 30 s of each trial. *Tlim significantly different from Leg2PL-CONTRA 643 
and Leg2ACT-CONTRA (P<0.05). 644 
 645 
Figure 6 646 
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Ratings of perceived exertion (RPE) during severe-intensity, single-leg knee-extensor exercise 647 
of the left leg in Leg1PL (filled circles) and Leg1ACT (clear circles) (panel A), in the right control 648 
leg (Leg2CON, open triangles), and in the right leg following prior exhaustive exercise in the left 649 
leg after PL ingestion (Leg2PL-CONTRA, filled circles) and ACT (Leg2ACT-CONTRA, clear circles) 650 
ingestion (panel B). Data are expressed as group mean ± SE. *Tlim significantly different from 651 
Leg2PL-CONTRA and Leg2ACT-CONTRA (P<0.05); 
#RPE significantly different from Leg2CON 652 
(P<0.05). 653 
